IP Library Granted Patent US 8,097,458
Granted Patent B2
US 8,097,458 · App. 12/763,884 · Granted Jan 17, 2012

Micro-carrier culture system for rapid expansion of human embryonic stem cells

Assignee: Geron Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,097,458
App. No.
12/763,884
Granted
Jan 17, 2012
Kind
B2
Abstract

This disclosure provides an improved system for culturing human pluripotent stem cells. Traditionally, pluripotent stem cells are cultured on a layer of feeder cells (such as mouse embryonic fibroblasts) to prevent them from differentiating. In the system described here, the role of feeder cells is replaced by components added to the culture environment that support rapid proliferation without differentiation. Effective features are a suitable support structure for the cells, and an effective medium that can be added fresh to the culture without being preconditioned by another cell type. Culturing human embryonic stem cells in fresh medium according to this invention causes the cells to expand surprisingly rapidly, while retaining the ability to differentiate into cells representing all three embryonic germ layers. This new culture system allows for bulk proliferation of pPS cells for commercial production of important products for use in drug screening and human therapy.

Claims (24)

1. A method of expanding primate pluripotent stem cells (pPS cell) in an undifferentiated state comprising a) attaching a pPS cell to a microcarrier comprising a matrix and b) providing the pPS cells with a nutrient media and c) expanding 2 fold the pPS cells in an undifferentiated state.

2. The method of claim 1 , wherein the matrix comprises an extracellular matrix protein.

3. The method of claim 1 , wherein the matrix comprises a soluble preparation of Engelbreth-Holm-Swarm tumor.

4. The method of claim 1 , wherein the nutrient media comprises 20% fetal bovine serum.

5. The method of claim 1 , wherein the nutrient media comprises 20% serum replacement.

6. The method of claim 1 , wherein the nutrient media comprises albumin.

7. The method of claim 1 , wherein the nutrient media comprises insulin,

8. The method of claim 1 , wherein the nutrient media comprises transferrin.

9. The method of claim 1 , wherein the nutrient media is a media conditioned by a cell.

10. The method of claim 1 , wherein the nutrient media is non-conditioned media comprising fibroblast growth factor (FGF).

11. The method of claim 10 wherein the FGF is FGF 2.

12. The method of claim 10 , wherein the FGF is FGF 4.

13. A method of expanding cells expressing the markers Oct 4, stage specific antigen 4 (SSEA4), Tra-1-60 and Tra-1-81 in an undifferentiated state comprising a) attaching the cells expressing the markers Oct 4, stage specific antigen 4 (SSEA4), Tra-1-60 and Tra-1-81 to a microcarrier comprising a matrix and b) providing the cells expressing the markers Oct 4, stage specific antigen 4 (SSEA4), Tra-1-60 and Tra-1-81 with a nutrient media and c) expanding 2 fold the cells expressing, the markers Oct 4, stage specific antigen 4 (SSEA4), Tra-1-60 and Tra-1-81 in an undifferentiated state.

14. The method of claim 13 , wherein the matrix comprises an extracellular matrix protein.

15. The method of claim 13 , wherein the matrix comprises a soluble preparation of Engelbreth-Holm-Swarm tumor.

16. The method of claim 13 , wherein the nutrient media comprises 20% fetal bovine serum.

17. The method of claim 13 , wherein the nutrient media comprises 20% serum replacement.

18. The method of claim 13 , wherein the nutrient media comprises albumin.

19. The method of claim 13 , wherein the nutrient media comprises insulin.

20. The method of claim 13 , wherein the nutrient media comprises transferrin.

21. The method of claim 13 , wherein the nutrient media is a media conditioned by a cell.

22. The method of claim 13 , wherein the nutrient media is non-conditioned media comprising fibroblast growth factor (FGF).

23. The method of claim 13 wherein the FGF is FGF 2.

24. The method of claim 13 , wherein the FGF is FGF 4.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2013
From: GERON CORPORATION
To: ASTERIAS BIOTHERAPEUITCS, INC.
Reel/Frame 031578/0054 →
Continuity (6)
Continuation 12710078 · Feb 22, 2010
Continuation 12170219 · Jul 9, 2008
Continuation 12763884
Continuation 10235094 · Sep 4, 2002
Provisional Application 60317478 · Sep 5, 2001
Related Publication 20100203633A1 · Aug 12, 2010